Literature DB >> 33591326

Challenging conventional karyotyping by next-generation karyotyping in 281 intensively treated patients with AML.

Sylvain Mareschal1,2, Anna Palau1, Johan Lindberg3, Philippe Ruminy4, Christer Nilsson5,6, Sofia Bengtzén5,6, Marie Engvall7, Anna Eriksson2, Anne Neddermeyer2, Vinciane Marchand4, Monika Jansson5,6, My Björklund2, Fabrice Jardin4,8, Mattias Rantalainen9, Andreas Lennartsson1, Lucia Cavelier7, Henrik Grönberg9, Sören Lehmann2,5,6.   

Abstract

Although copy number alterations (CNAs) and translocations constitute the backbone of the diagnosis and prognostication of acute myeloid leukemia (AML), techniques used for their assessment in routine diagnostics have not been reconsidered for decades. We used a combination of 2 next-generation sequencing-based techniques to challenge the currently recommended conventional cytogenetic analysis (CCA), comparing the approaches in a series of 281 intensively treated patients with AML. Shallow whole-genome sequencing (sWGS) outperformed CCA in detecting European Leukemia Net (ELN)-defining CNAs and showed that CCA overestimated monosomies and suboptimally reported karyotype complexity. Still, the concordance between CCA and sWGS for all ELN CNA-related criteria was 94%. Moreover, using in silico dilution, we showed that 1 million reads per patient would be enough to accurately assess ELN-defining CNAs. Total genomic loss, defined as a total loss ≥200 Mb by sWGS, was found to be a better marker for genetic complexity and poor prognosis compared with the CCA-based definition of complex karyotype. For fusion detection, the concordance between CCA and whole-transcriptome sequencing (WTS) was 99%. WTS had better sensitivity in identifying inv(16) and KMT2A rearrangements while showing limitations in detecting lowly expressed PML-RARA fusions. Ligation-dependent reverse transcription polymerase chain reaction was used for validation and was shown to be a fast and reliable method for fusion detection. We conclude that a next-generation sequencing-based approach can replace conventional CCA for karyotyping, provided that efforts are made to cover lowly expressed fusion transcripts.
© 2021 by The American Society of Hematology.

Entities:  

Year:  2021        PMID: 33591326      PMCID: PMC7903223          DOI: 10.1182/bloodadvances.2020002517

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  58 in total

1.  Multiplexed targeted sequencing of recurrent fusion genes in acute leukaemia.

Authors:  P Ruminy; V Marchand; N Buchbinder; T Larson; B Joly; D Penther; E Lemasle; S Lepretre; E Angot; S Mareschal; P-J Viailly; S Dubois; F Clatot; M Viennot; E Bohers; D Rizzo; M Cornic; P Bertrand; C Girod; V Camus; P Etancelin; G Buchonnet; P Schneider; J-M Picquenot; J-P Vannier; C Bastard; H Tilly; F Jardin
Journal:  Leukemia       Date:  2015-07-03       Impact factor: 11.528

2.  Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map.

Authors:  N Zhao; A Stoffel; P W Wang; J D Eisenbart; R Espinosa; R A Larson; M M Le Beau
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

3.  Adverse prognostic impact of abnormal lesions detected by genome-wide single nucleotide polymorphism array-based karyotyping analysis in acute myeloid leukemia with normal karyotype.

Authors:  Jun Ho Yi; Jungwon Huh; Hee-Jin Kim; Sun-Hee Kim; Hyeoung-Joon Kim; Yeo-Kyeoung Kim; Sang Kyun Sohn; Joon Ho Moon; Sung Hyun Kim; Kyoung Ha Kim; Jong Ho Won; Yeung Chul Mun; Hawk Kim; Jinny Park; Chul Won Jung; Dong Hwan Kim
Journal:  J Clin Oncol       Date:  2011-11-14       Impact factor: 44.544

4.  Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology: the Eastern Cooperative Oncology Group experience.

Authors:  E Paietta; J Racevskis; J M Bennett; D Neuberg; P A Cassileth; J M Rowe; P H Wiernik
Journal:  Leukemia       Date:  1998-12       Impact factor: 11.528

5.  Copy-number analysis identified new prognostic marker in acute myeloid leukemia.

Authors:  O Nibourel; S Guihard; C Roumier; N Pottier; C Terre; A Paquet; P Peyrouze; S Geffroy; S Quentin; A Alberdi; R B Abdelali; A Renneville; C Demay; K Celli-Lebras; P Barbry; B Quesnel; S Castaigne; H Dombret; J Soulier; C Preudhomme; M H Cheok
Journal:  Leukemia       Date:  2016-09-30       Impact factor: 11.528

6.  ALL-1 partial duplication in acute leukemia.

Authors:  S A Schichman; M A Caligiuri; Y Gu; M P Strout; E Canaani; C D Bloomfield; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

7.  DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly.

Authors:  Ilari Scheinin; Daoud Sie; Henrik Bengtsson; Mark A van de Wiel; Adam B Olshen; Hinke F van Thuijl; Hendrik F van Essen; Paul P Eijk; François Rustenburg; Gerrit A Meijer; Jaap C Reijneveld; Pieter Wesseling; Daniel Pinkel; Donna G Albertson; Bauke Ylstra
Journal:  Genome Res       Date:  2014-09-18       Impact factor: 9.043

8.  Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling.

Authors:  M Wang; J Lindberg; D Klevebring; C Nilsson; A S Mer; M Rantalainen; S Lehmann; H Grönberg
Journal:  Leukemia       Date:  2017-02-07       Impact factor: 11.528

9.  A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia.

Authors:  Stefan Gröschel; Mathijs A Sanders; Remco Hoogenboezem; Elzo de Wit; Britta A M Bouwman; Claudia Erpelinck; Vincent H J van der Velden; Marije Havermans; Roberto Avellino; Kirsten van Lom; Elwin J Rombouts; Mark van Duin; Konstanze Döhner; H Berna Beverloo; James E Bradner; Hartmut Döhner; Bob Löwenberg; Peter J M Valk; Eric M J Bindels; Wouter de Laat; Ruud Delwel
Journal:  Cell       Date:  2014-04-03       Impact factor: 41.582

10.  Haploinsufficiency of ETV6 and CDKN1B in patients with acute myeloid leukemia and complex karyotype.

Authors:  Simone Feurstein; Frank G Rücker; Lars Bullinger; Winfried Hofmann; Georgi Manukjan; Gudrun Göhring; Ulrich Lehmann; Michael Heuser; Arnold Ganser; Konstanze Döhner; Brigitte Schlegelberger; Doris Steinemann
Journal:  BMC Genomics       Date:  2014-09-11       Impact factor: 3.969

View more
  3 in total

Review 1.  The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH).

Authors:  F Nguyen-Khac; A Bidet; A Daudignon; M Lafage-Pochitaloff; G Ameye; C Bilhou-Nabéra; E Chapiro; M A Collonge-Rame; W Cuccuini; N Douet-Guilbert; V Eclache; I Luquet; L Michaux; N Nadal; D Penther; B Quilichini; C Terre; C Lefebvre; M-B Troadec; L Véronèse
Journal:  Leukemia       Date:  2022-04-16       Impact factor: 12.883

2.  A Study Protocol for Validation and Implementation of Whole-Genome and -Transcriptome Sequencing as a Comprehensive Precision Diagnostic Test in Acute Leukemias.

Authors:  Eva Berglund; Gisela Barbany; Christina Orsmark-Pietras; Linda Fogelstrand; Jonas Abrahamsson; Irina Golovleva; Helene Hallböök; Martin Höglund; Vladimir Lazarevic; Lars-Åke Levin; Jessica Nordlund; Ulrika Norèn-Nyström; Josefine Palle; Tharshini Thangavelu; Lars Palmqvist; Valtteri Wirta; Lucia Cavelier; Thoas Fioretos; Richard Rosenquist
Journal:  Front Med (Lausanne)       Date:  2022-03-24

3.  What Is Abnormal in Normal Karyotype Acute Myeloid Leukemia in Children? Analysis of the Mutational Landscape and Prognosis of the TARGET-AML Cohort.

Authors:  Morten Krogh Herlin; Sara A Yones; Eigil Kjeldsen; Linda Holmfeldt; Henrik Hasle
Journal:  Genes (Basel)       Date:  2021-05-21       Impact factor: 4.096

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.